Oncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation Therapy

Educational Event Aimed at Sharing Clinical Knowledge and Best Practices for Establishing an MR Image-guided Radiation Therapy Program

CLEVELAND, Dec. 19, 2017 /PRNewswire/ — Experts in MR image-guided radiation therapy will share their experiences during a global symposium to be held on Friday, March 16, 2018 in Amsterdam. The event aims to educate clinicians interested in bringing MR image-guided radiation therapy to their institution.

The symposium, titled “Advanced Applications of MR-Guided Radiotherapy Symposium,” will highlight a full spectrum of MR image-guided radiation therapy topics including underlying technical challenges and system considerations, as well as commissioning and quality assurance protocols. Additional presentations aim to share practical clinical knowledge, including discussions on clinical applications and early outcomes data. Other topics include the novel clinical use of on-table adaptive radiotherapy, real-time soft-tissue tracking and automated gating as well as related best clinical practices, workflows, etc.

The day-long event is intended for oncologists, medical physicists, administrators, and related clinical stakeholders interested in the clinical capabilities of an MR image-guided radiation therapy program in their facilities. Presenters include clinicians from VU University Medical Center (VUmc), University Hospital Heidelberg, University of Wisconsin, Washington University, and Henry Ford Health System. The event will conclude with a tour and overview of the MRIdian MR image-guided radiation therapy system at nearby VUmc.

“Changes in tumor size and its relation to nearby organs at risk are known to occur throughout radiation treatment courses, in addition to organ motion during radiation delivery. Prior to MR image-guidance, it was challenging, if not impossible, to observe these inter- and intrafractional changes,” said Martin Fuss, M.D., Ph.D., Executive Director of ViewRay’s Clinical Cooperative Think Tank (C2T2). “With MR image-guidance, radiation oncologists are able to see these changes in great detail for the first time during the treatments, and also have a toolset to adapt to changing anatomies while the patient is still on the treatment table. We are thankful that our clinical collaboration partners are willing to share their experience in the use of these technologies to advance the related science, and ultimately to provide treatment options more individualized for each cancer patient.”

The symposium is sponsored by ViewRay, makers of MRIdian, the world’s first and only commercially available MR image-guided radiation therapy system. There is no fee to attend, but space is limited to the first 150 registered attendees. To register, please visit https://mr-guidedrt.eventbrite.com.

About ViewRay

ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges including beam distortion, skin toxicity, and other safety concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include the advancement of science and the ability of MRI-guided radiation therapy programs to enable more treatment options.  Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.